O	0	10	Expression	Expression	NN	B-NP
O	11	13	of	of	IN	B-PP
O	14	25	thymidylate	thymidylate	NN	B-NP
O	26	34	synthase	synthase	NN	I-NP
O	35	38	and	and	CC	O
O	39	56	dihydropyrimidine	dihydropyrimidine	NN	B-NP
O	57	70	dehydrogenase	dehydrogenase	NN	I-NP
O	71	73	in	in	IN	B-PP
B-Cancer	74	81	primary	primary	JJ	B-NP
I-Cancer	82	86	oral	oral	JJ	I-NP
I-Cancer	87	95	squamous	squamous	JJ	I-NP
I-Cancer	96	100	cell	cell	NN	I-NP
I-Cancer	101	110	carcinoma	carcinoma	NN	I-NP
O	111	114	and	and	CC	O
O	115	128	corresponding	corresponding	JJ	B-NP
B-Cancer	129	139	metastases	metastasis	NNS	I-NP
O	140	142	in	in	IN	B-PP
B-Multi-tissue_structure	143	151	cervical	cervical	JJ	B-NP
I-Multi-tissue_structure	152	157	lymph	lymph	NN	I-NP
I-Multi-tissue_structure	158	163	nodes	node	NNS	I-NP
O	163	164	:	:	:	O
O	165	176	association	association	NN	B-NP
O	177	181	with	with	IN	B-PP
O	182	185	the	the	DT	B-NP
O	186	196	metastasis	metastasis	NN	I-NP
O	197	207	suppressor	suppressor	NN	I-NP
O	208	212	CD82	CD82	NN	I-NP
O	212	213	.	.	.	O

O	215	226	Thymidylate	Thymidylate	NN	B-NP
O	227	235	synthase	synthase	NN	I-NP
O	236	237	(	(	(	O
O	237	239	TS	TS	NN	B-NP
O	239	240	)	)	)	O
O	241	244	and	and	CC	O
O	245	262	dihydropyrimidine	dihydropyrimidine	NN	B-NP
O	263	276	dehydrogenase	dehydrogenase	NN	I-NP
O	277	278	(	(	(	O
O	278	281	DPD	DPD	NN	B-NP
O	281	282	)	)	)	O
O	283	286	are	be	VBP	B-VP
O	287	288	5	5	CD	B-NP
O	288	289	-	-	HYPH	I-NP
O	289	301	fluorouracil	fluorouracil	NN	I-NP
O	302	303	(	(	(	O
O	303	304	5	5	CD	B-NP
O	304	305	-	-	HYPH	I-NP
O	305	307	FU	FU	NN	I-NP
O	307	308	)	)	)	O
O	309	321	metabolizing	metabolize	VBG	B-VP
O	322	329	enzymes	enzyme	NNS	B-NP
O	330	333	and	and	CC	O
O	334	337	are	be	VBP	B-VP
O	338	346	involved	involve	VBN	I-VP
O	347	349	in	in	IN	B-PP
O	350	353	the	the	DT	B-NP
O	354	365	sensitivity	sensitivity	NN	I-NP
O	366	368	of	of	IN	B-PP
B-Cancer	369	378	carcinoma	carcinoma	NN	B-NP
O	379	387	patients	patient	NNS	I-NP
O	388	390	to	to	TO	B-PP
O	391	392	5	5	CD	B-NP
O	392	393	-	-	HYPH	I-NP
O	393	395	FU	FU	NN	I-NP
O	395	396	.	.	.	O

O	397	405	Although	Although	IN	B-SBAR
O	406	407	5	5	CD	B-NP
O	407	408	-	-	HYPH	I-NP
O	408	410	FU	FU	NN	I-NP
O	411	413	is	be	VBZ	B-VP
O	414	419	often	often	RB	I-VP
O	420	424	used	use	VBN	I-VP
O	425	428	for	for	IN	B-PP
O	429	432	the	the	DT	B-NP
O	433	442	treatment	treatment	NN	I-NP
O	443	445	of	of	IN	B-PP
B-Cancer	446	450	oral	oral	JJ	B-NP
I-Cancer	451	460	carcinoma	carcinoma	NN	I-NP
O	460	461	,	,	,	O
O	462	467	there	there	EX	B-NP
O	468	471	has	have	VBZ	B-VP
O	472	475	not	not	RB	I-VP
O	476	480	been	be	VBN	I-VP
O	481	484	any	any	DT	B-NP
O	485	498	investigation	investigation	NN	I-NP
O	499	503	into	into	IN	B-PP
O	504	507	the	the	DT	B-NP
O	508	518	expression	expression	NN	I-NP
O	519	521	of	of	IN	B-PP
O	522	527	these	these	DT	B-NP
O	528	535	enzymes	enzyme	NNS	I-NP
O	536	538	in	in	IN	B-PP
B-Multi-tissue_structure	539	549	metastatic	metastatic	JJ	B-NP
I-Multi-tissue_structure	550	555	lymph	lymph	NN	I-NP
I-Multi-tissue_structure	556	561	nodes	node	NNS	I-NP
O	562	564	or	or	CC	B-PP
O	565	567	of	of	IN	B-PP
O	568	573	their	their	PRP$	B-NP
O	574	579	roles	role	NNS	I-NP
O	580	582	in	in	IN	B-PP
O	583	586	the	the	DT	B-NP
O	587	600	effectiveness	effectiveness	NN	I-NP
O	601	603	of	of	IN	B-PP
O	604	605	5	5	CD	B-NP
O	605	606	-	-	HYPH	I-NP
O	606	608	FU	FU	NN	I-NP
O	609	611	in	in	IN	B-PP
O	612	620	treating	treat	VBG	B-VP
B-Cancer	621	626	lymph	lymph	NN	B-NP
I-Cancer	627	631	node	node	NN	I-NP
I-Cancer	631	632	-	-	HYPH	B-NP
I-Cancer	632	642	metastatic	metastatic	JJ	I-NP
I-Cancer	643	649	cancer	cancer	NN	I-NP
O	649	650	.	.	.	O

B-Cancer	651	655	Oral	Oral	JJ	B-NP
I-Cancer	656	664	squamous	squamous	JJ	I-NP
I-Cancer	665	669	cell	cell	NN	I-NP
I-Cancer	670	679	carcinoma	carcinoma	NN	I-NP
O	680	681	(	(	(	O
B-Cancer	681	685	OSCC	OSCC	NN	B-NP
O	685	686	)	)	)	O
O	687	692	often	often	RB	B-ADVP
O	693	705	metastasizes	metastasize	VBZ	B-VP
O	706	708	to	to	TO	B-PP
O	709	712	the	the	DT	B-NP
B-Multi-tissue_structure	713	718	lymph	lymph	NN	I-NP
I-Multi-tissue_structure	719	724	nodes	node	NNS	I-NP
O	724	725	,	,	,	O
O	726	729	and	and	CC	O
O	730	735	these	these	DT	B-NP
O	736	743	enzymes	enzyme	NNS	I-NP
O	744	747	may	may	MD	B-VP
O	748	750	be	be	VB	I-VP
O	751	762	significant	significant	JJ	B-ADJP
O	763	765	in	in	IN	B-PP
O	766	769	the	the	DT	B-NP
O	770	778	survival	survival	NN	I-NP
O	779	781	of	of	IN	B-PP
O	782	790	patients	patient	NNS	B-NP
O	791	795	with	with	IN	B-PP
O	796	800	this	this	DT	B-NP
O	801	808	disease	disease	NN	I-NP
O	808	809	.	.	.	O

O	810	814	This	This	DT	B-NP
O	815	820	study	study	NN	I-NP
O	821	833	investigated	investigate	VBD	B-VP
O	834	837	the	the	DT	B-NP
O	838	848	expression	expression	NN	I-NP
O	849	851	of	of	IN	B-PP
O	852	854	TS	TS	NN	B-NP
O	855	858	and	and	CC	I-NP
O	859	862	DPD	DPD	NN	I-NP
O	863	865	in	in	IN	B-PP
B-Cancer	866	874	cervical	cervical	JJ	B-NP
I-Cancer	875	880	lymph	lymph	NN	I-NP
I-Cancer	881	885	node	node	NN	I-NP
I-Cancer	886	896	metastases	metastasis	NNS	I-NP
O	897	900	and	and	CC	O
O	901	904	its	its	PRP$	B-NP
O	905	917	relationship	relationship	NN	I-NP
O	918	922	with	with	IN	B-PP
B-Cancer	923	930	primary	primary	JJ	B-NP
I-Cancer	931	935	OSCC	OSCC	NN	I-NP
O	935	936	,	,	,	O
O	937	939	as	as	RB	B-CONJP
O	940	944	well	well	RB	I-CONJP
O	945	947	as	as	IN	I-CONJP
O	948	951	the	the	DT	B-NP
O	952	963	interaction	interaction	NN	I-NP
O	964	971	between	between	IN	B-PP
O	972	977	these	these	DT	B-NP
O	978	985	enzymes	enzyme	NNS	I-NP
O	986	989	and	and	CC	O
O	990	996	Kangai	Kangai	NNP	B-NP
O	997	998	1	1	CD	I-NP
O	998	999	(	(	(	O
O	999	1003	KAI1	KAI1	NN	B-NP
O	1003	1004	/	/	SYM	B-NP
O	1004	1008	CD82	CD82	NN	I-NP
O	1008	1009	)	)	)	O
O	1010	1015	which	which	WDT	B-NP
O	1016	1018	is	be	VBZ	B-VP
O	1019	1020	a	a	DT	B-NP
O	1021	1031	metastasis	metastasis	NN	I-NP
O	1032	1042	suppressor	suppressor	NN	I-NP
O	1043	1050	protein	protein	NN	I-NP
O	1050	1051	.	.	.	O

B-Cancer	1052	1060	Surgical	Surgical	JJ	B-NP
I-Cancer	1061	1070	specimens	specimen	NNS	I-NP
O	1071	1075	from	from	IN	B-PP
O	1076	1078	20	20	CD	B-NP
O	1079	1084	cases	case	NNS	I-NP
O	1085	1087	of	of	IN	B-PP
B-Cancer	1088	1092	OSCC	OSCC	NN	B-NP
O	1093	1097	with	with	IN	B-PP
B-Multi-tissue_structure	1098	1103	lymph	lymph	NN	B-NP
I-Multi-tissue_structure	1104	1108	node	node	NN	I-NP
O	1109	1119	metastasis	metastasis	NN	I-NP
O	1119	1120	,	,	,	O
O	1121	1123	20	20	CD	B-NP
O	1124	1129	cases	case	NNS	I-NP
O	1130	1132	of	of	IN	B-PP
B-Cancer	1133	1137	OSCC	OSCC	NN	B-NP
O	1138	1145	without	without	IN	B-PP
B-Multi-tissue_structure	1146	1151	lymph	lymph	NN	B-NP
I-Multi-tissue_structure	1152	1156	node	node	NN	I-NP
O	1157	1167	metastasis	metastasis	NN	I-NP
O	1167	1168	,	,	,	O
O	1169	1172	and	and	CC	O
O	1173	1175	10	10	CD	B-NP
O	1176	1181	cases	case	NNS	I-NP
O	1182	1184	of	of	IN	B-PP
O	1185	1191	normal	normal	JJ	B-NP
B-Multi-tissue_structure	1192	1198	mucosa	mucosa	NN	I-NP
O	1199	1203	were	be	VBD	B-VP
O	1204	1212	examined	examine	VBN	I-VP
O	1213	1215	by	by	IN	B-PP
O	1216	1236	immunohistochemistry	immunohistochemistry	NN	B-NP
O	1236	1237	.	.	.	O

O	1238	1241	The	The	DT	B-NP
O	1242	1254	relationship	relationship	NN	I-NP
O	1255	1262	between	between	IN	B-PP
O	1263	1265	TS	TS	NN	B-NP
O	1266	1269	and	and	CC	O
O	1270	1273	DPD	DPD	NN	B-NP
O	1274	1284	expression	expression	NN	I-NP
O	1285	1288	and	and	CC	O
O	1289	1308	clinicopathological	clinicopathological	JJ	B-NP
O	1309	1313	data	datum	NNS	I-NP
O	1314	1317	was	be	VBD	B-VP
O	1318	1326	analyzed	analyze	VBN	I-VP
O	1326	1327	.	.	.	O

O	1328	1330	TS	TS	NN	B-NP
O	1331	1334	and	and	CC	I-NP
O	1335	1338	DPD	DPD	NN	I-NP
O	1339	1347	proteins	protein	NNS	I-NP
O	1348	1352	were	be	VBD	B-VP
O	1353	1366	overexpressed	overexpresse	VBN	I-VP
O	1367	1369	in	in	IN	B-PP
B-Cancer	1370	1377	primary	primary	JJ	B-NP
I-Cancer	1378	1382	OSCC	OSCC	NN	I-NP
O	1383	1391	compared	compare	VBN	B-VP
O	1392	1394	to	to	TO	B-PP
O	1395	1399	that	that	DT	B-NP
O	1400	1402	in	in	IN	B-PP
O	1403	1409	normal	normal	JJ	B-NP
B-Multi-tissue_structure	1410	1416	mucosa	mucosa	NN	I-NP
O	1416	1417	.	.	.	O

O	1418	1420	TS	TS	NN	B-NP
O	1421	1431	expression	expression	NN	I-NP
O	1432	1434	of	of	IN	B-PP
O	1435	1438	the	the	DT	B-NP
B-Cell	1439	1446	primary	primary	JJ	I-NP
I-Cell	1447	1451	oral	oral	JJ	I-NP
I-Cell	1452	1458	cancer	cancer	NN	I-NP
I-Cell	1459	1464	cells	cell	NNS	I-NP
O	1465	1467	in	in	IN	B-PP
O	1468	1471	the	the	DT	B-NP
O	1472	1477	group	group	NN	I-NP
O	1478	1482	with	with	IN	B-PP
B-Multi-tissue_structure	1483	1488	lymph	lymph	NN	B-NP
I-Multi-tissue_structure	1489	1493	node	node	NN	I-NP
O	1494	1504	metastasis	metastasis	NN	I-NP
O	1505	1508	was	be	VBD	B-VP
O	1509	1515	higher	high	JJR	B-ADJP
O	1516	1520	than	than	IN	B-PP
O	1521	1525	that	that	DT	B-NP
O	1526	1528	of	of	IN	B-PP
O	1529	1534	those	those	DT	B-NP
O	1535	1542	without	without	IN	B-PP
O	1542	1543	.	.	.	O

O	1544	1547	DPD	DPD	NN	B-NP
O	1548	1558	expression	expression	NN	I-NP
O	1559	1562	did	do	VBD	B-VP
O	1563	1566	not	not	RB	I-VP
O	1567	1580	significantly	significantly	RB	I-VP
O	1581	1590	correlate	correlate	VB	I-VP
O	1591	1595	with	with	IN	B-PP
O	1596	1599	the	the	DT	B-NP
O	1600	1610	occurrence	occurrence	NN	I-NP
O	1611	1613	of	of	IN	B-PP
B-Multi-tissue_structure	1614	1619	lymph	lymph	NN	B-NP
I-Multi-tissue_structure	1620	1624	node	node	NN	I-NP
O	1625	1635	metastasis	metastasis	NN	I-NP
O	1635	1636	,	,	,	O
O	1637	1640	nor	nor	CC	O
O	1641	1644	was	be	VBD	O
O	1645	1647	it	it	PRP	B-NP
O	1648	1657	different	different	JJ	B-ADJP
O	1658	1665	between	between	IN	B-PP
B-Cell	1666	1673	primary	primary	JJ	B-NP
I-Cell	1674	1678	oral	oral	JJ	I-NP
I-Cell	1679	1685	cancer	cancer	NN	I-NP
I-Cell	1686	1691	cells	cell	NNS	I-NP
O	1692	1695	and	and	CC	O
B-Cancer	1696	1704	cervical	cervical	JJ	B-NP
I-Cancer	1705	1715	metastases	metastasis	NNS	I-NP
O	1715	1716	.	.	.	O

O	1717	1721	CD82	CD82	NN	B-NP
O	1722	1732	expression	expression	NN	I-NP
O	1733	1736	was	be	VBD	B-VP
O	1737	1750	significantly	significantly	RB	I-VP
O	1751	1758	reduced	reduce	VBN	I-VP
O	1759	1761	in	in	IN	B-PP
B-Cancer	1762	1767	lymph	lymph	NN	B-NP
I-Cancer	1768	1772	node	node	NN	I-NP
I-Cancer	1773	1783	metastases	metastasis	NNS	I-NP
O	1783	1784	.	.	.	O

O	1785	1790	These	These	DT	B-NP
O	1791	1799	findings	finding	NNS	I-NP
O	1800	1808	indicate	indicate	VBP	B-VP
O	1809	1813	that	that	IN	B-SBAR
O	1814	1816	TS	TS	NN	B-NP
O	1817	1820	and	and	CC	I-NP
O	1821	1825	CD82	CD82	NN	I-NP
O	1826	1829	may	may	MD	B-VP
O	1830	1832	be	be	VB	I-VP
O	1833	1835	of	of	IN	B-PP
O	1836	1841	great	great	JJ	B-NP
O	1842	1847	value	value	NN	I-NP
O	1848	1850	in	in	IN	B-PP
O	1851	1860	assessing	assess	VBG	B-VP
B-Multi-tissue_structure	1861	1866	lymph	lymph	NN	B-NP
I-Multi-tissue_structure	1867	1871	node	node	NN	I-NP
O	1872	1882	metastasis	metastasis	NN	I-NP
O	1883	1885	of	of	IN	B-PP
B-Cancer	1886	1890	OSCC	OSCC	NN	B-NP
O	1890	1891	,	,	,	O
O	1892	1895	and	and	CC	O
O	1896	1901	could	could	MD	B-VP
O	1902	1904	be	be	VB	I-VP
O	1905	1910	taken	take	VBN	I-VP
O	1911	1913	as	as	IN	B-PP
O	1914	1917	new	new	JJ	B-NP
O	1918	1925	targets	target	NNS	I-NP
O	1926	1929	for	for	IN	B-PP
O	1930	1937	therapy	therapy	NN	B-NP
O	1938	1940	of	of	IN	B-PP
B-Cancer	1941	1951	metastatic	metastatic	JJ	B-NP
I-Cancer	1952	1956	OSCC	OSCC	NN	I-NP
O	1956	1957	.	.	.	O

